Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment

Medicine (United States)

Volumn 95, Issue 25, 2016, Pages

  Ni, Yang ^a   Bi, Jingwang ^b   Ye, Xin ^a   Fan, Weijun ^c   Yu, Guohua ^d   Yang, Xia ^a   Huang, Guanghui ^a   Li, Wenhong ^a   Wang, Jiao ^a   Han, Xiaoying ^a   Ni, Xiang ^a   Wei, Zhigang ^a   Han, Mingyong ^a   Zheng, Aimin ^a   Meng, Min ^a   Xue, Guoliang ^b   Zhang, Liang ^c   Wan, Chao ^c  

^a SHANDONG UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

acquired resistance; EGFR TKI; microwave ablation; non small cell lung cancer; oligoprogressive disease

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GLUCOCORTICOID; SNAKE VENOM; THROMBIN; PROTEIN KINASE INHIBITOR;

ABLATION DEVICE; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; DRUG RESISTANCE; EXTRACENTRAL NERVOUS SYSTEM OLIGOPROGRESSIVE DISEASE; FATIGUE; FEVER; FOLLOW UP; HEMOPTYSIS; HUMAN; MAJOR CLINICAL STUDY; MALAISE; METASTASIS; MICROWAVE THERMOTHERAPY; MUTATION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FEMALE; LUNG NEOPLASMS; MALE; MICROWAVE RADIATION; MIDDLE AGED; MULTICENTER STUDY; NERVOUS SYSTEM DISEASES; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; THERAPEUTIC USE; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MICROWAVES; MIDDLE AGED; NEOPLASM STAGING; NERVOUS SYSTEM DISEASES; PILOT PROJECTS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84976435972     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003998     Document Type: Article

References (34)

1. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
2. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947-57.
3. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
4. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34.
5. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
7. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
8. Paz-Ares L, Soulieres D, Melezinek I, et al. Clinical outcomes in nonsmall-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010;14:51-69.
9. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357-60.
10. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
11. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7.
12. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptormutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501.
13. Kosaka T, Yatabe Y, EndohH, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-9.
14. Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-Targeted therapy in lung cancer. Nat Genet 2012;44:852-60.
15. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
16. Nurwidya F, Takahashi F, Murakami A, et al. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 2012;44:151-6.
17. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFRmutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3:90ra59.
18. Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298-303.
19. Yoshimura N, Okishio K, Mitsuoka S, et al. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol 2013;8:96-101.
20. Kuiper JL, Smit EF. Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors. Oncology 2014;87:83-94.
21. Matikas A, Mistriotis D, Georgoulias V, et al. Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR-TKIs. Clin Lung Cancer 2015;16:252-61.
22. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-Addicted non-small-cell lung cancer. J Thorac Oncol 2012;7:1807-14.
23. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8:346-51.
24. Ridge CA, Solomon SB, Thornton RH. Thermal ablation of stage I nonsmall cell lung carcinoma. Semin Intervent Radiol 2014;31:118-24.
25. Wei Z, Ye X, Yang X, et al. Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. Cardiovasc Intervent Radiol 2015;38:135-42.
26. Yang X, Ye X, Zheng A, et al. Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases. J Surg Oncol 2014;110:758-63.
27. Wei Z, Ye X, Yang X, et al. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. Med Oncol 2015;32:464.
28. Zheng A, Wang X, Yang X, et al. Major complications after lung microwave ablation: a single-center experience on 204 sessions. Ann Thorac Surg 2014;98:243-8.
29. Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 2010;116:1336-43.
30. Crocetti L, Bozzi E, Faviana P, et al. Thermal ablation of lung tissue: in vivo experimental comparison of microwave and radiofrequency. Cardiovasc Intervent Radiol 2010;33:818-27.
31. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in nonsmall cell lung cancer on progression-free and overall survival: a metaanalysis. J Natl Cancer Inst 2013;105:595-605.
32. Wu SG, Yang CH, Yu CJ, et al. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 2011;72:333-9.
33. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-52.
34. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014;11: 473-81.